Recent Press Releases

Adempas® Approved in Japan for the Treatment of Pulmonary Arterial Hypertension

Adempas® Approved in Japan for the Treatment of Pulmonary Arterial Hypertension Berlin, February 20, 2015 – Bayer Healtcare announced that Adempas® (riociguat) has received approval for...

Lilly Provides Update on Evacetrapib Phase 3 Trial

INDIANAPOLIS, Feb.

Sanofi Appoints Olivier Brandicourt as Chief Executive Officer

Sanofi Appoints Olivier Brandicourt as Chief Executive Officer - Tenure as CEO will commence on April 2, 2015 - Paris - February 19, 2015 - The Board of Directors unanimously appointed Olivier...

Genentech Statement on Protocol T Trial Data in the New England Journal of Medicine

Genentech Statement on Protocol T Trial Data in the New England Journal of Medicine SOUTH SAN FRANCISCO, Calif. -- February 18th, 2015 -- The Diabetic Retinopathy Clinical Research Network's...

FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID®...

NICE gives EYLEA a provisional green light to treat patients with visual impairment due to DMO

NICE gives EYLEA a provisional green light to treat patients with visual impairment due to DMO The National Institute for Health and Care Excellence (NICE) draft decision recommends EYLEA for the...

NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab

NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and...

Attorney General DeWine Requests Rebates from Naloxone Manufacturer

(COLUMBUS, Ohio)— Ohio Attorney General Mike DeWine announced today he is requesting that Amphastar Pharmaceuticals, Inc., a manufacturer of naloxone, provide rebates to consumers such as...

Johnson & Johnson Announces Patent and Trademark Office Action Related to REMICADE®

NEW BRUNSWICK, N.J., Feb. 12, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced receipt of a further action from the Patent and Trademark Office regarding the re-examination of...

Actavis Non-GAAP Net Revenue Increases 44% to $4 Billion in Fourth Quarter 2014; Non-GAAP EPS Increases 23% to $3.91; Increases 2015 Standalone Forecast

- Adjusted EBITDA Increases 80% to $1.5 Billion in Fourth Quarter 2014 - - $12.8 Billion Full Year Non-GAAP Net Revenue Increases 48% - - $4.5 Billion Full Year Adjusted EBITDA Increases 99% - -...

Actavis Announces Intention to Adopt "Allergan" Corporate Name

- Unites Global Brand Portfolio Under Allergan Name - - Retains Actavis Name for Select Geographic Regions and Product Portfolios- - Recognizes Heritage and Customer Equity of Both Names - - Company...

ASTRAZENECA ANNOUNCES NON-EXECUTIVE BOARD CHANGES

AstraZeneca today announced that Dr Cornelia (Cori) Bargmann will be proposed to shareholders for election as a Non-Executive Director at the Company's Annual General Meeting (AGM) on 24 April 2015....

Actavis to Divest Pharmatech to TPG

-- TPG to Focus Company on Growth and Development of Innovative Products-- --Divestiture Allows Actavis to Sharpen Focus on Supporting Existing Global Supply Chain Network-- DUBLIN, IRELAND...

NICE issues final draft guidance on pomalidomide for blood cancer

NICE issues final draft guidance on pomalidomide for blood cancer NICE has issued final draft guidance not recommending pomalidomide, also known as Imnovid, for treating multiple myeloma. Multiple...

ABBVIE SUBMITS NEW DRUG APPLICATION IN JAPAN FOR ITS INVESTIGATIONAL, ALL-ORAL, TREATMENT FOR CHRONIC HEPATITIS C

- SUBMISSION BASED ON PHASE 3 GIFT-I STUDY IN PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C VIRUS INFECTION - GIFT-I MET ITS PRIMARY ENDPOINT, ACHIEVING 95 PERCENT SUSTAINED VIROLOGIC RESPONSE RATE...

Students with Type 1 Diabetes Get a Boost from Lilly Diabetes to Attend College

Lilly Diabetes supports scholarships through donation to Diabetes Scholars Foundation

ROLLING MEADOWS, Ill. and

Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon

02/10/2015 LAVAL, Quebec, Feb. 10, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that they have been advised by Dendreon Corporation that...

Leading US Companies Announce Major Healthcare Investment in London

LONDON, February 9, 2015 /PRNewswire/ -- London's status as a leading centre for the life sciences, financial and digital industries has attracted significant new investment by two leading US...